PRX-08066 is an orally active 5-HT2BR Antagonist with Vasodilation Effect for PAH
Pulmonary arterial hypertension (PAH) is an increased pulmonary arterial pressure caused by vasoconstriction and pulmonary vascular remodeling. In addition, 5-hydroxytryptamine (5-HT) plays a role in the development of PAH. Specifically,…